A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial
Name
1745-6215-14-46.pdf
Size
852.11 KB
Format
Adobe PDF
Checksum (MD5)
1fca723cbd12981130ad4ee7732cc08d
Author(s)
Jolicœur, E. Marc
Banai, Shmuel
Henry, Timothy D.
Schwartz, Marc
Doucet, Serge
White, Christopher J.
Edelman, Elazer R.
Verheye, Stefan
Date Issued
February 2013
Journal
Trials
Publisher
BioMed Central Ltd.
Citation
Jolicœur, E Marc et al. “A Phase II, Sham-controlled, Double-blinded Study Testing the Safety and Efficacy of the Coronary Sinus Reducer in Patients with Refractory Angina: Study Protocol for a Randomized Controlled Trial.” Trials 14.1 (2013): 46. CrossRef. Web.
Version
Final published version
Abstract
Background
A growing population of patients lives with severe coronary artery disease not amenable to coronary revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can improve the symptoms of refractory angina in patients with limited revascularization options.
Methods/Design
The COSIRA trial is a phase II double-blind, sham-controlled, randomized parallel trial comparing the percutaneously implanted coronary sinus Reducer (Neovasc Inc, Richmond, BC, Canada) to a sham implantation in 124 patients enrolled in Canada, Belgium, England, Scotland, Sweden and Denmark. All patients need to have stable Canadian Cardiovascular Society (CCS) class III or IV angina despite optimal medical therapy, with evidence of reversible ischemia related to disease in the left coronary artery, and a left ventricular ejection fraction >25%. Participants experiencing an improvement in their angina ≥2 CCS classes six months after the randomization will meet the primary efficacy endpoint. The secondary objective of this trial is to test whether coronary sinus Reducer implantation will improve left ventricular ischemia, as measured by the improvement in dobutamine echocardiogram wall motion score index and in time to 1 mm ST-segment depression from baseline to six-month post-implantation.
Discussion
Based on previous observations, the COSIRA is expected to provide a significant positive result or an informative null result upon which rational development decisions can be based. Patient safety is a central concern and extensive monitoring should allow an appropriate investigation of the safety related to the coronary sinus Reducer.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1186/1745-6215-14-46
